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Inhibition of interleukin 6 (IL-6) signalling has been proposed as a potential cardi-
oprotective strategy for patients with chronic kidney disease (CKD), but the direct
effects of IL-6 inhibition on renal function are not known. A Mendelian randomiza-
tion (MR) study was performed to investigate the association of genetically proxied
inhibition of IL-6 signalling with estimated glomerular filtration rate (eGFR), CKD and
blood urea nitrogen (BUN). Inverse-variance weighted MR was used as the main anal-
ysis, with sensitivity analyses performed using simple median, weighted median and
MR-Egger methods. There was no evidence for an association of genetically proxied
inhibition of IL-6 signalling (scaled per standard deviation unit decrease in C-reactive
protein) with log eGFR (0.001, 95% confidence interval −0.004-0.007), BUN (0.009,
95% confidence interval −0.003-0.021) and CKD (odds ratio 0.948, 95% confidence
interval 0.822-1.094). These findings do not raise concerns for IL-6 signalling having
large adverse effects on renal function.
K E YWORD S
cardiovascular disease, chronic kidney disease, interleukin-6, Mendelian randomization study
1 | INTRODUCTION
Cardiovascular disease (CVD) accounts for half of all deaths in end-
stage renal failure and the burden of CVD in chronic kidney disease
(CKD) is not fully explained by traditional risk factors.1 This suggests
that alternative pathways may be implicated in the disproportionately
high CVD risk in patients with declining renal function.2 CKD is recog-
nized as a low-grade but persistent inflammatory state, with raised
levels of inflammatory biomarkers such as interleukin-1β (IL-1β),
interleukin-6 (IL-6) and C-reactive protein (CRP).3 Inflammation plays
a critical role in atherosclerosis and it is possible that the inflammatory
milieu of CKD contributes to the excessive risk of CVD in CKD.4,5
Inflammatory markers including high-sensitive CRP and IL-6 are pre-
dictive of cardiovascular events and IL-6 levels are independent pre-
dictors of CVD and mortality in patients with CKD.6,7 Pharmacological
inhibition of IL-1β by the monoclonal antibody canakinumab has
reduced rates of major cardiovascular events in patients with CKD
who had a previous myocardial infarction.8 Further analysis of can-
akinumab showed that the cardioprotective effect was dependent on
inhibition of IL-6 levels in a general population.9 There are now ongo-
ing plans to commence trials of the IL-6 signalling inhibitor
ziltivekimab for reduction of CVD in patients with CKD.10 However, it
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has not been established whether or not direct IL-6 signalling inhibi-
tion has an impact on renal function.
Mendelian randomization (MR) employs genetic polymorphisms as
instrumental variables to study the effect of an exposure on an out-
come.11 MR is less susceptible to confounding due to the random allo-
cation of genetic variants and balancing of environmental factors at
conception. For a valid MR study, the following assumptions must hold:
the genetic proxy must be associated with the exposure, the genetic
variant only affects the outcome through the exposure of interest with
no horizontal pleiotropic effect and the genetic variant is not associ-
ated with any known confounder affecting the exposure and the out-
come.11 A valid MR study is analogous to an endogenous randomized
controlled trial based on the randomization of genetic variants at con-
ception. Applied to drug development, MR provides an in silico plat-
form to predict adverse drug consequences, explore drug repurposing
and determine whether or not new therapeutic strategies are suitable
to be trialled among vulnerable populations, such as patients with
CKD.12 Considering the growing interest in IL-6 inhibition in patients
with CKD, the aim of the present study was to investigate the effect of
inhibition of IL-6 signalling on renal function by MR methods.
2 | METHODS
A two-sample MR study was conducted to investigate the association
of genetically proxied inhibition of IL-6 signalling with different mea-
sures of renal function: estimated glomerular filtration rate (eGFR),
CKD and blood urea nitrogen (BUN). Two-sample refers to the fact
that the instrument-exposure and instrument-outcome estimate are
obtained from two different genome-wide association studies (GWAS),
in this case serving to increase the statistical power of the MR study.
Genetic variants for downregulated IL-6 signalling were selected
as uncorrelated (r2 < 0.1) single-nucleotide polymorphism (SNPs)
within 300 kB of the IL-6 receptor gene (IL6R, GRCh37/hg19 coordi-
nates: chr1:154077669-154 741 926) that is associated with CRP in
the UK Biobank12 (n = 337 199, White British ancestry individuals) at
genome-wide significance (P < 5E-8). CRP is a reliable downstream
marker for IL-6 signalling and thus variants in the IL6R gene which
associate with CRP levels represent proxies for IL-6 signalling modula-
tion. To further investigate the validity of the selected variants, we
measured the Pearson coefficient for the correlation between their
association with CRP and other markers of IL-6 signalling, IL6R and
serum IL-6 levels, obtained from an independent GWAS.13 The vari-
ance in CRP levels explained by the genetic variants, R2, was calcu-
lated using the formula: R2 = [2 × MAF × (1 – MAF) × β2], where MAF
is the minor allele frequency and β is the effect estimate of the SNP
on CRP levels. F-statistics, a measure of instrument strength in MR,
were calculated using the formula: F = R2 × (n − 2)/(1 − R2) where n is
the number of individuals in the GWAS analysis.
Summary GWAS data from the Chronic Kidney Disease Genetics
(CKDGen) Consortium European ancestry meta-analyses were used
to obtain genetic association estimates for the primary outcomes of
log eGFR, BUN and CKD (Table 1).14 There are no overlapping
populations between the exposure and outcome GWAS. In the origi-
nal study, log eGFR was calculated using the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation in adults and using
the Schwartz formula for participants who were 18 years or younger.
CKD was constructed as a binary outcome based on an
eGFR < 60 mL min−1 per 1.73 m2. BUN was calculated as 2.8 × blood
urea (mg/dL). Power was calculated using an online tool (https://
shiny.cnsgenomics.com/mRnd) to estimate the minimum and maxi-
mum effects that we had 80% statistical power to detect.
Data for the exposure and outcome were harmonized according
to the effect allele and no exclusions were made for palindromic vari-
ants. Individual MR estimates were calculated using the Wald ratio.
Heterogeneity was assessed using Cochran's Q statistic and to
account for heterogeneity a random-effects inverse-variance
weighted method was used for the primary MR analysis. To explore
potential pleiotropy, we conducted sensitivity analyses using the sim-
ple median, weighted median and MR-Egger methods. The median
methods are robust if less than 50% of the contribution to the MR
estimates comes from invalid instrumental variables.15 MR-Egger pro-
vides robust estimates even when all instrumental variables are inva-
lid, as long as the INstrument Strength Independent of Direct Effect
(INSIDE) assumption holds: that any pleiotropic effect of the variants
on the outcome are independent of the strength of their association
with the exposure.15 The estimated MR-Egger intercept is indicative
of the average pleiotropic effect of the variants used.15 We tested for
such pleiotropy by assessing whether our intercept was significantly
different from zero.15 Results are presented as effect estimates and
corresponding 95% confidence intervals per standard deviation
decrease in CRP levels. For eGFR and BUN, respectively, estimates
represent the change in log eGFR or blood urea nitrogen, and for CKD
the results are expressed as odds ratio for CKD. All data analyses
What is already known about this subject
• Inhibition of interleukin 6 (IL-6) signalling has shown
promising potential for lowering cardiovascular risk.
• Patients with chronic kidney disease (CKD) have a high
burden of cardiovascular disease, likely mediated in part
due to a low-grade and persistent inflammatory state.
• There is growing interest in using IL-6 inhibitors to
reduce cardiovascular risk in patients with CKD.
What this study adds
• This Mendelian randomization study did not identify evi-
dence to support the association of genetically proxied
inhibition of IL-6 signalling with changes in renal
function.
• Adverse effects on renal function directly related to IL-6
inhibition are unlikely to limit this therapeutic strategy for
reducing cardiovascular disease risk in patients with CKD.
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were performed using “TwoSampleMR” package version 4.26 in R
statistical software.
In further sensitivity analysis, we repeated our analysis using a
different set of instrumental variables that have been used in a previ-
ous study to proxy IL-6 signalling inhibition.16 These variants were
selected based on associations with CRP (P < 5E-8, clumped at
r2 < 0.1) in the Cohorts for Heart and Aging Research in Genomic Epi-
demiology (CHARGE) Inflammation Working Group GWAS of
204 402 individuals of European ancestry.17 Data from UK Biobank
was chosen for the primary analysis because there were overlapping
studies between exposure and outcome data sources.
3 | RESULTS
Thirty SNPs were used as instrumental variables to represent geneti-
cally proxied inhibition of IL-6 signalling (Table 2). The F-statistic for
the genetic exposure associations ranged between 40.28 and
1713.82 (median 98.0), indicating strong associations between the
IL6-R variants and CRP level (Table 2). The genetic association with
CRP in the UK Biobank showed a high degree of correlation with
other markers of IL-6 signalling: IL6R (r = −0.90, P = 1.75E-11) and
serum IL-6 levels (r = −0.80, P = 6.2E-4, Appendix 1).
In the main analysis, there was no strong evidence for an associa-
tion of genetically proxied inhibition of IL-6 inhibition with log eGFR
(0.001, 95% confidence interval −0.004-0.007), BUN (0.009, 95%
confidence interval −0.003-0.021) and CKD (odds ratio 0.948, 95%
confidence interval 0.822-1.094). The results were consistent across
all considered measures of renal function (Figure 1). There was evi-
dence of heterogeneity in the main MR analyses for eGFR and CKD,
but no heterogeneity for BUN (Appendix 2). The MR-Egger intercepts
did not identify evidence of pleiotropy for eGFR, BUN or CKD
(P = 0.912, P = 0.798 and P = 0.681, respectively). Individual SNP
associations are provided in Appendix 3. Similar results were obtained
in sensitivity analyses using instrumental variables obtained from the
CHARGE consortium (Appendix 5).
4 | DISCUSSION
This MR study did not identify evidence to show that genetically
proxied inhibition of IL-6 signalling has an effect on renal function.
IL-6 inhibitors such as tocilizumab are currently licenced for use in
rheumatoid arthritis, juvenile arthritis and more recently have been
under investigation for treatment of excessive inflammation in
patients with severe acute respiratory syndrome coronavirus 2 infec-
tion.18 Atherosclerotic cardiovascular disease is an inflammatory dis-
order and both MR studies and randomized controlled trials suggest
that inhibition of IL-6 signalling reduces risk of cardiovascular out-
comes and thromboembolic events.16,19 Given the disproportionate
burden of cardiovascular disease in patients with CKD and the inflam-
matory nature of both these conditions, there is growing interest in
repurposing IL-6 inhibitors to treat CVD in CKD.10 Our current find-
ings support pharmacological IL-6 inhibition being unlikely to have a
direct adverse effect on renal function.
The findings of this MR study are in line with an earlier study of
renal function in patients with rheumatoid arthritis and renal insuffi-
ciency receiving tocilizumab therapy.20 However, this observational
study is small (120 participants), had large numbers of patient stop-
ping or switching therapy (60% switching biological therapy) and may
be susceptible to confounding factors (patients receiving IL-6 inhibi-
tion were older and had rheumatoid arthritis for longer).20 More
TABLE 1 Data sources for exposure and outcomes
Data Data source
Population
ancestry Sample size Exposure definition Adjustments
Genetic variants in or
near IL-6R associated
with variation in CRP
UK Biobank12 White
British
337 199 Standard deviation change
in CRP (4.35 mg/L) per
copy increment of the
effect allele







meta-analysis (n = 24
studies)14
European 243 029 Change in BUN (mg/dL)
per copy increment of
effect allele
Sex and age in all included
studies, with some
studies in the meta-
analysis further








meta-analysis (n = 42
studies)14
European 567 460 Change in log eGFR
(mL min−1 per 1.73 m2)















Log odds ratio for CKD per
copy increment of effect
allele
Table 1 describes the source, population ancestry, sample size and exposure definitions for the genome-wide association studies used in the present
Mendelian randomization analysis.
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recently, the Il-1β inhibitor canakinumab, which also inhibits IL-6, was
trialled in patients with CKD and showed no effect on renal function
in terms of serial eGFR, creatinine and urinary albumin-creatinine
ratio.8 The present MR study adds support to the initial
pharmacovigilance surveys, and further is less prone to confounding
and reverse causation. The manufacturer of tocilizumab (tradename
Actemra) advises that no dose adjustment is required for patients with
mild renal impairment, but cautions that the drug has not been studied
in patients with moderate to severe renal dysfunction.21 This high-
lights a potential limitation of available clinical trial data: despite over
10% of patients in the developed world having renal impairment,
patients with CKD are excluded from up to 75% of all randomized-
controlled trials.22 MR may help in evaluating the safety of drugs in
silico prior to trials in patients. For example, MR drug safety studies
have in the past substantiated the causal relationship between inhibi-
tion of IL-6 signalling and increased risk of pneumonia.18 Furthermore,
MR can provide more immediate drug safety information compared to
usual pharmacovigilance strategies, such as the Medicines and
Healthcare Products Regulatory Agency yellow card scheme.
Our study has a number of strengths. In an attempt to minimize
the bias related to pleiotropic effects of variants, instrumental vari-
ables were selected based on their proximity to the IL6R gene and in
relation to reliable biomarkers of IL-6 signalling. In addition, the MR-
Egger method did not provide evidence to suggest biasing pleiotropy.
TABLE 2 Instrumental variables: variants employed as instrumental variables to proxy inhibition of IL-6 signalling (associations with
C-reactive protein are detailed)
SNP Effect allele Other allele Effect allele frequency Beta Standard error P value R2 F
rs112505856 T C 0.039 −0.046 0.006 8.82E-13 1.58E-04 74.48
rs16835819 C T 0.018 −0.077 0.009 7.73E-18 2.15E-04 101.05
rs61806853 C T 0.050 −0.044 0.006 2.26E-15 1.79E-04 84.22
rs79505546 T C 0.017 −0.054 0.009 7.21E-09 9.62E-05 45.2
rs1194610 C T 0.235 0.020 0.003 6.01E-13 1.48E-04 69.47
rs67156297 A G 0.262 0.036 0.003 9.96E-40 4.97E-04 233.76
rs12077265 G T 0.155 −0.056 0.003 6.24E-64 8.20E-04 385.54
rs4133213 A C 0.450 −0.086 0.003 1.00E-200 3.63E-03 1713.82
rs79219014 T G 0.028 −0.086 0.007 1.26E-31 3.92E-04 184.24
rs186110340 G C 0.024 0.056 0.008 5.02E-12 1.48E-04 69.61
rs139952834 T C 0.013 0.062 0.011 3.36E-08 9.84E-05 46.23
rs113580743 A G 0.039 0.049 0.006 4.12E-15 1.81E-04 85.11
rs139460294 C T 0.016 −0.059 0.010 4.48E-09 1.06E-04 49.83
rs140615642 C T 0.020 −0.078 0.009 8.53E-19 2.37E-04 111.53
rs116059394 G A 0.059 0.049 0.005 8.73E-21 2.60E-04 122.33
rs56100876 A G 0.019 −0.109 0.009 2.35E-33 4.41E-04 207.24
rs4845645 A T 0.173 −0.051 0.003 1.31E-55 7.34E-04 344.98
rs77994623 T C 0.167 0.047 0.003 7.08E-49 6.16E-04 289.57
rs76289529 T C 0.038 −0.047 0.006 8.22E-14 1.64E-04 76.86
rs12750774 A G 0.316 −0.064 0.003 1.33E-137 1.77E-03 834.94
rs147483024 T G 0.018 0.066 0.010 7.47E-12 1.55E-04 73.01
rs3766925 A T 0.227 −0.016 0.003 4.12E-08 8.57E-05 40.28
rs12059682 C T 0.206 0.046 0.003 5.39E-55 6.97E-04 327.51
rs188727323 T C 0.189 −0.044 0.003 5.35E-39 5.80E-04 272.64
rs4845657 C T 0.199 0.040 0.003 1.49E-39 5.03E-04 236.5
rs12757447 G T 0.016 −0.063 0.010 1.43E-10 1.23E-04 58
rs79753070 A G 0.025 −0.052 0.008 8.96E-11 1.29E-04 60.64
rs34693607 G C 0.214 −0.033 0.003 2.09E-29 3.62E-04 170.15
rs11264245 T C 0.057 −0.029 0.005 3.12E-08 8.78E-05 41.25
rs7523010 A T 0.213 0.025 0.003 2.13E-15 2.02E-04 94.96
Table 2 shows the summary data for the variants that proxy IL-6 signalling inhibition. SNP, single-nucleotide polymorphism. Beta is the standard deviation
unit change in CRP (4.35 mg/L) per copy increment in the effect allele. R2 represents the variance in CRP explained by the respective genetic variant. The
F-statistic measures the strength of the instrumental variable with the exposure. In an additive model assuming independent variants, these instrumental
variables explain 0.0138 of the variance in the exposure.
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Our results were robust to sensitivity analysis where different SNPs
to proxy IL-6 signalling inhibition were selected from an independent
GWAS. Furthermore, the consistency of our results across different
MR methods and different measurements of renal dysfunction further
substantiates the null findings.
Our study also has limitations. The analysis for eGFR was well-
powered and it is unlikely that the null finding for eGFR represents a
type II error for a clinically relevant effect. There was less power to
detect small differences for BUN and CKD due to the smaller number
of participants or cases, respectively, in the GWAS. It is important to
interpret our findings within the context of an MR study, which con-
siders genetically proxied inhibition of IL-6 signalling, rather than the
effect of a discrete clinical intervention. Our approach looks at IL-6
signalling in isolation, and it is possible that pharmacological IL-6
inhibitors could have off-target effects (aside from IL-6R signalling) on
other renal or extrarenal pathways which may ameliorate or exacer-
bate renal function indirectly. There is also the possibility of drug-drug
interactions that cannot be accounted for in the present MR analysis.
In conclusion, this study is consistent with the hypothesis that
inhibition of IL-6 signalling does not directly affect renal function,
supporting this approach as a therapeutic opportunity for reducing
the risk of CVD in patients with CKD.
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APPENDIX 1: Genetic association estimates for variants proxying the effect of IL-6 inhibition
Genetic proxies for interleukin 6 (IL-6) inhibition selected on basis of their association with C-reactive protein (CRP), and the corresponding asso-






Beta estimate for association
with CRP (UK Biobank)
Beta estimate for association
with IL6R (INTERVAL study)
Beta estimate for association with
serum IL-6 (INTERVAL study)
rs112505856 T C −0.046 0.316
rs16835819 C T −0.077 0.453
rs61806853 C T −0.044 0.496
rs79505546 T C −0.054 0.356
rs1194610 C T 0.020 0.190
rs67156297 A G 0.036 −0.254 −0.254
rs12077265 G T −0.056 −0.075 −0.044
rs4133213 A C −0.086 0.974 0.084
rs79219014 T G −0.086 0.758 0.087
rs186110340 G C 0.056 −0.548
rs139952834 T C 0.062 −0.651
rs113580743 A G 0.049 −0.514
rs139460294 C T −0.058 0.384 0.136
rs140615642 C T −0.078 0.547
rs116059394 G A 0.048 −0.576 −0.064
rs56100876 A G −0.109 0.584
rs4845645 A T −0.051 0.219 0.082
rs77994623 T C 0.047 −0.618
rs76289529 T C −0.047 0.666 0.107
rs12750774 A G −0.064 0.549 0.057
rs147483024 T G 0.066 −0.308 −0.156
rs3766925 A T −0.016 0.184 −0.049
rs12059682 C T 0.046 −0.383 −0.055
rs188727323 T C −0.043
rs4845657 C T 0.040 −0.273
rs12757447 G T −0.063 0.253
rs79753070 A G −0.052 0.571 0.142
rs34693607 G C −0.033 0.196 0.058
rs11264245 T C −0.029 0.447
rs7523010 A T 0.025 −0.049
Pearson correlations:
• Correlation between CRP and IL6R association: r = −0.90, P = 1.8E-11
• Correlation between CRP and IL-6 association: r = −0.80, P = 6.2E-4
Table showing the association between SNPs and CRP, IL-6 receptor and serum IL-6 level. SNP, single nucleotide polymorphism. Beta is the stan-
dard deviation unit change in CRP, IL-6 alpha subunit or IL-6 level per copy increment in the effect allele. The association between individual vari-
ants and CRP was established in the UK Biobank. Associations between individual variants and IL-6 receptor and serum IL-6 were obtained from
the INTERVAL study13 as made publicly available through the PhenoScanner database.23 Missing cells infer no data was available for the respec-
tive variant in the INTERVAL study.
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TABLE A1 Chronic kidney disease: effects of genetically proxied IL-6 inhibition on chronic kidney disease
Method Estimate (standard error) Odds ratio (95% confidence interval) P value
Inverse-variance weighted −0.053 (0.073) 0.948 (0.822-1.094) 0.474
Simple median −0.081 (0.103) 0.922 (0.754-1.128) 0.431
Weighted median −0.059 (0.094) 0.943 (0.784-1.133) 0.528
MR-Egger 0.013 (0.174) 1.013 (0.720-1.425) 0.942
MR-Egger intercept −0.004 (0.174) 0.996 (0.708-1.401) 0.681
Cochran's Q-statistic: inverse-variance weighted analysis 35.38 (SNPs 27), P = 0.13.
TABLE A2 Log estimated glomerular
filtration rate: association of genetically
proxied inhibition of IL-6 signalling with
log odds of estimated glomerular
filtration rate
Method Estimate (standard error) 95% confidence interval P value
Inverse-variance weighted 0.001 (0.003) −0.004-0.007 0.599
Simple median 0.002 (0.004) −0.007-0.010 0.721
Weighted median 0.002 (0.004) −0.005-0.009 0.620
MR-Egger 0.001 (0.007) −0.012-0.014 0.908
MR-Egger intercept 0.0004 (0.0003) −0.0006-0.0007 0.912
Cochran's Q-statistic: inverse-variance weighted analysis 37.93 (SNPs 27), P = 0.08.
TABLE A3 Blood urea nitrogen:
effects of genetically proxied IL-6
inhibition on blood urea nitrogen
Method Estimate (standard error) 95% confidence interval P value
Inverse-variance weighted 0.009 (0.006) −0.003-0.021 0.121
Simple median 0.005 (0.011) −0.017-0.027 0.666
Weighted median 0.012 (0.009) −0.006-0.030 0.183
MR-Egger 0.004 (0.014) −0.023-0.031 0.798
MR-Egger intercept 0.0003 (0.0007) −0.0016-0.001 0.662
Cochran's Q-statistic: inverse-variance weighted analysis 22.24 (SNPs 25), P = 0.62.
APPENDIX 2: Mendelian randomization sensitivity analysis estimates for the association of genetically proxied inhibition of IL-6 signalling
with measures of renal function
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F IGURE A1 Chronic kidney disease:
associations of genetically proxied IL-6 inhibition
on chronic kidney disease for each instrumental
variable. Forest plot showing the individual Wald
ratios and 95% confidence intervals for each
variant used in the primary analysis. Pooled
estimates using inverse-variance weighted, simple
median, weighted median and MR-Egger are
shown in red
APPENDIX 3: Individual Wald ratios Forest Plots
RYAN ET AL. 9
F IGURE A2 Blood urea nitrogen: associations
of genetically proxied IL-6 inhibition on blood
urea nitrogen for each instrumental variable.
Forest plot showing the individual Wald ratios
with 95% confidence intervals for each variant
used in the primary analysis. Pooled estimates
using inverse-variance weighted, simple median,
weighted median and MR-Egger are shown in red
F IGURE A3 Log estimated glomerular
filtration rate (eGFR): associations of genetically
proxied IL-6 inhibition on eGFR for each
instrumental variable. Forest plot showing the
individual Wald ratios with 95% confidence
intervals for each variant used in the primary
analysis. Pooled estimates using inverse-variance
weighted, simple median, weighted median and
MR-Egger are shown in red
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APPENDIX 4: Power calculations for the primary Mendelian randomization analyses
Table detailing the minimum and maximum estimates that the primary analysis had 80% statistical power to detect. Power calculation were based
on the online application: https://shiny.cnsgenomics.com/mRnd. The total variance explained by the variants was estimated using their total R2.
Continuous outcomes
Phenotype n total Detectable MR-estimate at 80% power
Log eGFR 567 460 ≤−0.0000405, ≥0.000034
BUN 243 029 ≤−0.0158, ≥0.0157
Categorical outcomes
Phenotype n total (% cases) Detectable OR at 80% power
CKD 480 698 (8.6%) ≤0.879 or ≥1.124
APPENDIX 5: Sensitivity analysis using variants from the CHARGE Consortium
Instrumental variables from the CHARGE Consortium: variants employed as instrumental variables to proxy inhibition of IL-6 signalling. Associa-
tions with C-reactive protein are detailed. Instruments (n = 7) were selected by based on the association of variants within 300kB of the IL6R
gene with CRP in the CHARGE GWAS. These were originally identified by Georgakis et al.16
SNP Effect allele Other allele Effect allele frequency Beta Standard error P value R2 F
rs73026617 T C 0.097 0.0474 0.0068 3.16E-12 3.58E-04 73.16
rs12083537 A G 0.193 0.0643 0.0053 7.14E-34 1.17E-03 239.60
rs4556348 T C 0.148 0.0541 0.0067 6.77E-16 6.71E-04 137.25
rs2228145 A C 0.36 0.0899 0.0042 1.21E-101 3.39E-03 694.37
rs11264224 A C 0.193 0.0465 0.0057 3.41E-16 6.12E-04 125.23
rs12059682 T C 0.196 −0.0441 0.0049 2.26E-19 5.57E-04 113.96
rs34693607 C G 0.184 0.0368 0.0057 1.07E-10 3.70E-04 75.59
Table showing the summary data for the variants that proxy IL-6 signalling inhibition. SNP, single nucleotide polymorphism. Beta is the unit
change in natural log transformed CRP (mg/L) per copy increment in the effect allele. R2 represents the variance in CRP explained by the respec-
tive genetic variant. The F-statistic measures the strength of the instrumental variable with the exposure. Variants identified and associated well
with IL-6 signalling inhibition in a previous Mendelian randomization study exploring IL-6 inhibition and effects on ischaemic stroke and cardiovas-
cular outcomes.16
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TABLE A4 Chronic kidney disease: association of genetically proxied IL-6 inhibition on chronic kidney disease
Method Estimate (standard error) Odds ratio (95% confidence interval) P value
Inverse-variance weighted −0.018 (0.052) 0.982 (0.887-1.087) 0.723
Simple median −0.009 (0.111) 0.991 (0.797-1.232) 0.936
Weighted median −0.006 (0.088) 0.994 (0.837-1.181) 0.943
MR-Egger 0.105 (0.239) 1.11 (0.695-1.774) 0.678
MR-Egger intercept −0.008 (0.011) 0.992 (0.971-1.013) 0.490
Cochran's Q statistic: Inverse-variance weighted analysis: 2.96 (SNPs 6), P = 0.814.
TABLE A5 Log estimated glomerular
filtration rate: association of genetically
proxied inhibition of IL-6 signalling with
log odds of estimated glomerular
filtration rate
Method Estimate (standard error) 95% confidence interval P value
Inverse-variance weighted 0.001 (0.004) −0.007-0.009 0.862
Simple median −0.004 (0.005) −0.014-0.006 0.376
Weighted median −0.001 (0.003) −0.007-0.005 0.688
MR-Egger −0.006 (0.013) −0.031-0.019 0.687
MR-Egger intercept 0.0004 (0.0008) −0.002-0.001 0.636
Cochran's Q statistic: Inverse-variance weighted analysis 11.98 (SNPs 5), P = 0.062.
TABLE A6 Blood urea nitrogen:
association of genetically proxied IL-6
inhibition on blood urea nitrogen
Method Estimate (standard error) 95% confidence interval P value
Inverse-variance weighted 0.008 (0.007) −0.006-0.022 0.218
Simple median 0.003 (0.010) −0.017-0.023 0.759
Weighted median 0.008 (0.009) −0.01-0.026 0.350
MR-Egger 0.029 (0.023) −0.016-0.074 0.260
MR-Egger intercept −0.001 (0.001) −0.003-0.001 0.353
Cochran's Q statistic: inverse-variance weighted analysis 5.30 (SNPs 5), P = 0.505
APPENDIX 6: Estimates for the association of genetically proxied inhibition of IL-6 signalling with measures of renal function in sensitivity
analysis
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Sensitivity analysis: variants from the CHARGE consortium
Effects of genetically proxied IL-6 signal inhibition on renal function
Chronic kidney disease
Log estimated glomerular filtration rate
Blood urea nitrogen
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Forest plots showing the Mendelian randomization estimates for chronic kidney disease (CKD), log eGFR (estimated glomerular filtration rate) and
blood urea nitrogen (BUN) with different analysis methods (simple median, weighted median, inverse-variance weighted, MR-Egger). eGFR and
BUN are presented as causal estimates with 95% confidence interval. CKD is described as the odds ratio (95% confidence interval) of having CKD
with genetically proxied IL-6 signalling inhibition.
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